ALK and pneumonitis: We present a patient with echinoderm microtubule-associated protein-like 4 (EML4) and ALK fusion protein-positive mNSCLC who developed severe hypoxemia and pneumonitis requiring intubation within 2 days of initiating brigatinib therapy.